Strength Stack –
LGD4033 + MK2866 + RAD140

Research Compound Bundle | Triple SARM Formulation

The Strength Stack by Vi Corpus brings together three investigational selective androgen receptor modulators (SARMs): LGD-4033 (Ligandrol), MK-2866 (Ostarine) and RAD-140 (Testolone).

Each compound has been investigated for its interaction with androgen receptors, with scientific research examining receptor selectivity, tissue-specific activity, pharmacokinetics and androgen-mediated biological pathways.

This three-bottle research bundle provides each compound separately in a 30 mL liquid formulation, allowing their individual chemical and pharmacological characteristics to be identified.

What's Included

Compound	Concentration	Bottle Size	Quantity
LGD-4033 (Ligandrol) – Extreme Physique	10 mg/mL	30 mL	1 bottle
MK-2866 (Ostarine) – Vascular	33 mg/mL	30 mL	1 bottle
RAD-140 (Testolone)	15 mg/mL	30 mL	1 bottle

Total Package: 3 × 30 mL bottles (90 mL).

Compound Information

LGD-4033 (Ligandrol) – Extreme Physique

LGD-4033, also known as Ligandrol or VK5211, is an investigational nonsteroidal selective androgen receptor modulator (SARM).

LGD-4033 has been studied for its selective interaction with androgen receptors, particularly in research involving skeletal muscle, bone tissue and androgen-mediated physiological processes.

Scientific investigations have examined its pharmacokinetic characteristics, receptor selectivity and hormonal responses.

Key Research Areas:

• Selective androgen receptor binding
• Skeletal muscle and bone-related signalling pathways
• Androgen receptor-mediated cellular responses
• Pharmacokinetics and metabolic characteristics
• Endocrine and hormonal feedback mechanisms

MK-2866 (Ostarine) – Vascular

MK-2866, commonly referred to as Ostarine or Enobosarm, is an investigational nonsteroidal selective androgen receptor modulator.

MK-2866 has been evaluated in clinical research investigating androgen receptor activity and its relationship with skeletal muscle physiology and hormone-sensitive tissues.

Research has explored its tissue-selective properties, pharmacodynamics and potential effects on biological pathways regulated by androgen receptors.

Key Research Areas:

• Androgen receptor selectivity and signalling
• Skeletal muscle physiology
• Tissue-specific pharmacological responses
• Pharmacokinetic and pharmacodynamic characteristics
• Androgen receptor activity in clinical research

RAD-140 (Testolone)

RAD-140, also known as Testolone or Vosilasarm, is an investigational nonsteroidal selective androgen receptor modulator.

RAD-140 has been investigated for its interaction with androgen receptors and its tissue-selective pharmacological characteristics.

Unlike testosterone and conventional anabolic androgenic steroids, RAD-140 has a nonsteroidal chemical structure. Research has examined its receptor-binding properties, biological activity and pharmacokinetic behaviour.

Key Research Areas:

• Selective androgen receptor binding and activation
• Androgen receptor signalling pathways
• Tissue-selective pharmacological activity
• Nonsteroidal androgen receptor modulators
• Pharmacokinetic and metabolic characteristics

Product Specifications

Specification	Details
Product Name	Strength Stack
Brand	Vi Corpus
Compound 1	LGD-4033 (Ligandrol)
Compound 2	MK-2866 (Ostarine / Enobosarm)
Compound 3	RAD-140 (Testolone / Vosilasarm)
Compound Classification	Selective Androgen Receptor Modulators (SARMs)
LGD-4033 CAS Number	1165910-22-4
MK-2866 CAS Number	841205-47-8
RAD-140 CAS Number	1182367-47-0
LGD-4033 Concentration	10 mg/mL
MK-2866 Concentration	33 mg/mL
RAD-140 Concentration	15 mg/mL
Form	Liquid formulations
Bottle Size	30 mL each
Total Bottles	3
Total Volume	90 mL
Intended Purpose	Laboratory research only

Research and Scientific Background

LGD-4033, MK-2866 and RAD-140 belong to the nonsteroidal SARM class and have been investigated for their interactions with androgen receptors.

Although these compounds share a common receptor target, they differ in chemical structure, pharmacokinetic properties and the extent of their available scientific evidence.

Research involving SARMs has examined androgen receptor selectivity, skeletal muscle biology, bone-related signalling pathways and endocrine responses.

However, individual research findings do not establish the safety, effectiveness or clinical outcomes of administering these three compounds together.

Important Research Disclaimer

LGD-4033, MK-2866 and RAD-140 are investigational selective androgen receptor modulators and are not approved for human therapeutic use in Australia.

This information is provided for scientific and technical reference purposes only. It does not constitute a recommendation for personal administration, performance enhancement, bodybuilding cycles or treatment of medical conditions.

The safety and efficacy of combining these three compounds have not been established. SARMs may be associated with significant adverse effects, including hormonal suppression, liver injury and cardiovascular risks.

No claims are made regarding the safety, efficacy or therapeutic benefits of the combined formulation.